View On Demand

An Unconventional Weapon in the War on Cancer

About the Event

Immunicom has developed a hybrid cancer therapy which combines the best of a medical device with targeted drug therapy.

This revolutionary therapeutic platform delivers the drugs via a proprietary external extraction cartridge connected to existing plasma filtration equipment in oncology infusion centers. Immunicom is approved in Europe (CE Mark) for Triple Negative Breast Cancer and received FDA Breakthrough Technology Designation as a Class 3 PMA which streamlines the approval process in the U.S.

Join our webinar with Immunicom CEO, Amir Jafri, whose experience leading business development for Cardinal Health gives the company great insights into commercialization options in the very near future.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.